OS2.7 An open-labelled, randomized phase II study in patients with recurrent Glioblastoma Multiforme comparing progression free survival of ALECSAT (Autologous lymphoid effector cells specific against tumour-cells) versus Bevacizumab/Irinotecan

BACKGROUND: The aim of this study was to investigate the efficacy of ALECSAT (Autologous lymphoid effector cells specific against tumour-cells) in patients with recurrent glioblastoma multiforme (GBM). ALECSAT is a cell based medical product formulated as a patient specific suspension for injection....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Haslund, C., Muhic, A., Lukacova, S., Lund, B., Lassen-Ramshad, Y., Meyer, M., Roland, M., Skovgaard Poulsen, H.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
OS2 Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5782517/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.017
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados